Prognostic factors and health-related quality of life in ocular myasthenia gravis (OMG)

References

• Osserman EF, Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 1971;38:497–537.
   PubMed Web of Science ®Google Scholar
• Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America; Jaretzki A III, Barohn RJ, Ernstoff RM, Myasthenia gravis: recommendations for clinical research standards. Neurology 2000;55:16–23.
   PubMedGoogle Scholar
• Bedlack RS, Simel DL, Bosworth H, Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 2005;64:1968–70.
   PubMed Web of Science ®Google Scholar
• Citterio A, Beghi E, Millul A, Risk factors for tumour occurrence in patients with myasthenia gravis. J Neurol 2009;256:1221–7.
   PubMedGoogle Scholar
• Skeie GO, Romi F. Paraneoplastic myasthenia gravis: immunological and clinical aspects. Eur J Neurol 2008;15:1029–33.
   PubMed Web of Science ®Google Scholar
• Angelini C. Diagnosis and management of autoimmune myasthenia gravis. Clin Drug Investig 2011;31:1–14.
   PubMedGoogle Scholar
• Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord 2006;16:459–67.
   PubMed Web of Science ®Google Scholar
• Vincent A. Immunology of disorders of neuromuscular transmission. Acta Neurol Scand 2006; Suppl 183:1–7.
   Google Scholar
• Vincent A. Antibody-mediated disorders of neuromuscular transmission. Suppl Clin Neurophysiol 2004;57:147–58.
   PubMedGoogle Scholar
• Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2003;2:99–106.
   PubMed Web of Science ®Google Scholar
• Vincent A, Leite MI. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 2005;18:519–25.
   PubMed Web of Science ®Google Scholar
• Leite MI, Jacob S, Viegas S, IgG1 antibodies to acetylcholine receptors in “seronegative” mysthenia gravis. Brain 2008;131:1940–52
   PubMed Web of Science ®Google Scholar
• Argov Z. Current approach to seronegative myasthenia. J Neurol 2011;258:14–8.
   PubMedGoogle Scholar
• Vincent A, Rothwell P. Myasthenia gravis. Autoimmunity 2004;37:317–9.
   PubMed Web of Science ®Google Scholar
• Kawaguchi N, Kuwabara S, Nemoto Y, Treatment and outcome of myasthenia gravis: retrospective multi-center analysis of 470 Japanese patients, 1999–2000. J Neurol Sci 2004;224:43–7.
   PubMedGoogle Scholar
• Bartoccioni E, Scuderi F, Minicuci GM, Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 2006;67:505–7.
   PubMed Web of Science ®Google Scholar
• Lindstrom JM. Is “seronegative” MG explained by autoantibodies to MuSK? Neurology 2004;62:1920–1.
   PubMed Web of Science ®Google Scholar
• Gronseth GS, Barohn RJ. Thymectomy for Myasthenia gravis. Curr Treat Options Neurol 2002;4:203–9.
   PubMedGoogle Scholar
• Mantegazza R, Baggi F, Antozzi C, Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 2003;998:413–23.
   PubMed Web of Science ®Google Scholar
• Skeie GO, Apostolski S, Evoli A, Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010;17:893–902
   PubMed Web of Science ®Google Scholar
• Romi F, Gilhus NE, Varhaug JE, Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis. Eur J Neurol 2002;9:55–61.
   PubMed Web of Science ®Google Scholar
• Keesey JC. “Crisis” in myasthenia gravis: an historical perspective. Muscle Nerve 2002;26:1–3.
   PubMedGoogle Scholar
• Romi F, Gilhus NE, Varhaug JE, Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study. Eur J Neurol 2003;10:701–6.
   PubMed Web of Science ®Google Scholar
• Sanders DB, El-Salem K, Massey JM, Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60:1978–80.
   PubMed Web of Science ®Google Scholar
• Lindstrom J M. Acetylcholine receptors and myasthenia Muscle Nerve 2000;23:453–77.
   PubMed Web of Science ®Google Scholar
• Somnier FE. Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology 2005; 65:928–30.
   PubMed Web of Science ®Google Scholar
• Aragonès JM, Bolíbar I, Bonfill X, Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 2003;60:1024–6.
   PubMed Web of Science ®Google Scholar
• Hellmann MA, Mosberg-Galili R, Steiner I. Myasthenia gravis in the elderly. J Neurol Sci 2013;325:1–5.
   PubMed Web of Science ®Google Scholar
• Aarli JA. Myasthenia gravis in the elderly is it different? Ann N Y Acad Sci 2008;1132:238–43.
   PubMed Web of Science ®Google Scholar
• Casetta I, Groppo E, De Gennaro R, Myasthenia gravis: a changing pattern of incidence. J Neurol 2010;257: 2015–9.
   PubMed Web of Science ®Google Scholar
• Živković S, Clemens PR, Lacomis D. Characteristics of late-onset myasthenia gravis. J Neurol 2012;259:2167–71.
   PubMed Web of Science ®Google Scholar
• Matsui N, Nakane S, Nakagawa Y, Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan. J Neurol Neurosurg Psychiatry 2009;80: 1168–71.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Tanaka K, Fukuuchi Y. Prognosis after thymectomy in older patients with myasthenia gravis. J Am Geriatr Soc 2001;49:1257–8.
   PubMedGoogle Scholar
• Suzuki S, Utsugisawa K, Nagane Y, Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol 2011;230: 148–52.
   PubMed Web of Science ®Google Scholar
• Stojkovic T, Béhin A. Ocular myasthenia: diagnosis and treatment. Rev Neurol 2010;166:987–97.
   PubMedGoogle Scholar
• Cleary M, Williams GJ, Metcalfe RA. The pattern of extra-ocular muscle involvement in ocular myasthenia. Strabismus 2008;16:11–8.
   PubMedGoogle Scholar
• Monsul NT, Patwa HS, Knorr AM, The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 2004;217:131–3
   PubMed Web of Science ®Google Scholar
• Allen JA, Scala S, Royden Jones H. Ocular myasthenia gravis in a senior population: diagnosis, therapy and prognosis. Muscle Nerve 2010;41:379–84
   PubMedGoogle Scholar
• Bhanushali MJ, Wuu JM, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology 2008;71:1335–41.
   PubMed Web of Science ®Google Scholar
• Kusner LL, Puwanant A, Kaminski HJ. Ocular myasthenia: diagnosis, treatment, and pathogenesis. Neurologist 2006;12:231–9.
   PubMedGoogle Scholar
• Benatar M, Kaminski HJ. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standard Subcommitte of the American Academy of Neurology. Neurology 2007;68:2144–9.
   PubMedGoogle Scholar
• Kupersmith MJ. Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease? J Neurol Sci 2004;217:123–4.
   PubMedGoogle Scholar
• Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003;60:243–8.
   PubMedGoogle Scholar
• Zach H, Cetin H, Hilger E, The effect of early prednisolone treatment on generalization. Eur J Neurol 2013;20:708–13.
   PubMed Web of Science ®Google Scholar
• Mercelis R, Merckaert V. Diagnostic utility of stimulated single-fiber electromyography of the orbicularis oculi muscle in patients with suspected ocular myasthenia. Muscle Nerve 2011;43:168–70.
   PubMedGoogle Scholar
• Katzberg HD, Barnett C, Bril V. Predictors of response to immunemodulation in patients with myasthenia gravis. Muscle Nerve 2012;45:648–52.
   PubMed Web of Science ®Google Scholar
• Burns TM, Graham CD, Rose MR, Simmons Z. Quality of life and measures of quality of life in patients with neuromuscular disorders. Muscle Nerve 2012;46:9–25.
   PubMed Web of Science ®Google Scholar
• Burns TM, Conaway M, Sanders DB and the MG composite and MG-QOL 15 Study Group The MG Composite: A valid and reliable outcome measure for myasthenia gravis. Neurology 2010;74:1434–40.
   PubMed Web of Science ®Google Scholar
• Sadjadi R, Conaway M, Cutter G, Psychometric evaluation of the myasthenia gravis composite using Rasch analysis. Muscle Nerve 2012;45:820–5.
   PubMed Web of Science ®Google Scholar
• Muppidi S, Wolfe IG, Conaway M, Burns T, and the MG composite and MG-QOL 15 study group. MG-ADL: still a relevant outcome measure. Muscle Nerve 2011;44: 727–31.
   PubMed Web of Science ®Google Scholar
• Padua L, Evoli A, Aprile I, Health related quality of life in patients with Myasthenia Gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 2001;22:363–9.
   PubMed Web of Science ®Google Scholar
• Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980;103:579–601
   PubMed Web of Science ®Google Scholar
• Maniaol A, Elsais A, Lorentzen ÅR, Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLos One 2012;7:e36603.
   PubMed Web of Science ®Google Scholar
• Saruhan-Direskeneli G, Kiliç A, Parman Y, HLA-DQ polymorphism in Turkish patients with myasthenia gravis. Hum Immunol 2006;67:352–8.
   PubMed Web of Science ®Google Scholar
• Niks EH, Kuks JB, Roep BO, Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006;66:1772–4
   PubMed Web of Science ®Google Scholar
• Vandiedonck C, Beaurain G, Giraud M, Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia. Proc Natl Acad Sci USA 2004;101:15464–9.
   PubMed Web of Science ®Google Scholar
• Vandiedonck C, Giraud M, Garchon HJ. Genetics of autoimmune myasthenia gravis: the multifaceted contribution of the HLA complex. J Autoimmun 2005;25 Suppl: 6–11.
   PubMedGoogle Scholar
• Testi M, Terracciano C, Guagnano A, Association of HLA–DQB1*05:02 and DRB1*16 alleles with late-onset, nonthymomatous, AchR-Ab-positive myasthenia gravis. Autoimmune Dis 2012;2012:541760.
   PubMedGoogle Scholar
• Okumura M, Ohta M, Tateyama H, The world health organisation histologic classification system reflects the oncologic behavior of thymoma A clinical study of 273 patients. Cancer 2002;94:624–32.
   PubMed Web of Science ®Google Scholar
• Lavrnic D, Nikolic A, De Baets M, Familial occurrence of autoimmune myasthenia gravis with different antibody specificity Neurology. 2008;70:2011–3
   Google Scholar
• Paul RH, Nash JM, Cohen RA, Gilchrist JM, Goldstein JM. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 2001;24:512–6.
   PubMed Web of Science ®Google Scholar
• Kulkantrakorn K, Sawanyawisuth K, Tiamkao S. Factors correlating quality of life in patients with myasthenia gravis. Neurol Sci 2010;31:571–3.
   PubMed Web of Science ®Google Scholar
• Kehir MK, Burns TM, Alpers J, Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve 2010;41:593–8
   PubMedGoogle Scholar
• Raggi A, Leonardi M, Antozzi C, Concordance between severity of disease, disability and health-related quality of life in myasthenia gravis. Neurol Sci 2010;31:41–5.
   PubMed Web of Science ®Google Scholar
• Benatar M, Sanders DB, Wolfe GI, Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial. Ann N Y Acad Sci 2012;1275:17–22
   PubMed Web of Science ®Google Scholar